Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Total Caladrius Biosciences, Inc. Stockholders' Equity	Series B Convertible Preferred Stock	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Treasury Stock	Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2016			10,000	8,206,000
Beginning Balance at Dec. 31, 2016	$ 4,066	$ 4,883	$ 0	$ 8	$ 410,372	$ 0	$ (404,789)	$ (708)	$ (817)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	22,228	22,979					22,979		(751)
Unrealized loss on marketable securities	(28)	(28)				(28)
Share-based compensation (in shares)				54,000
Share-based compensation	2,494	2,494		$ 0	2,494
Net proceeds from issuance of common stock (in shares)				1,220,000
Net proceeds from issuance of common stock	5,701	5,701		$ 1	5,700
Proceeds from option exercises (in shares)				4,000
Proceeds from option exercises	14	14		$ 0	14
Elimination of equity associated with PCT sale	(3,686)								(3,686)
Conversion of redeemable securities	19,400	14,734			14,734				4,666
Change in ownership in subsidiary	0	(270)			(270)				270
Ending Balance (in shares) at Dec. 31, 2017			10,000	9,484,000
Ending Balance at Dec. 31, 2017	50,189	50,507	$ 0	$ 9	433,044	(28)	(381,810)	(708)	(318)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(16,168)	(16,167)					(16,167)		(1)
Unrealized loss on marketable securities	(4)	(4)				(4)
Share-based compensation (in shares)				129,000
Share-based compensation	2,053	2,053		$ 0	2,053
Net proceeds from issuance of common stock (in shares)				176,000
Net proceeds from issuance of common stock	1,029	1,029		$ 1	1,028
Proceeds from option exercises (in shares)				77,000
Proceeds from option exercises	355	355		$ 0	355
Change in ownership in subsidiary	0	(47)			(47)				47
Ending Balance (in shares) at Dec. 31, 2018			10,000	9,866,000
Ending Balance at Dec. 31, 2018	$ 37,454	$ 37,726	$ 0	$ 10	$ 436,433	$ (32)	$ (397,977)	$ (708)	$ (272)